Dr. Wagner

John L. Wagner, MD

Contact Dr. Wagner

864 Chestnut Street
Suite 315
Philadelphia, PA 19107

(215) 955-8874
(215) 503-4563 fax

Most Recent Peer-reviewed Publications

  1. Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition
  2. Higher rates of relapse in maternal recipients of haploidentical hematopoietic stem cell transplantation from adult offspring donors for AML and myelodysplastic syndrome
  3. Acquired uniparental disomy in chromosome 6p as a feature of relapse after T-cell replete haploidentical hematopoietic stem cell transplantation using cyclophosphamide tolerization
  4. A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation
  5. A two-step approach to myeloablative haploidentical transplantation: Low nonrelapse mortality and high survival confirmed in patients with earlier stage disease
  6. Investigation of a Clostridium difficile cluster by multilocus sequence typing in a bone marrow transplant unit
  7. Clostridium difficile colonization and disease in patients undergoing hematopoietic stem cell transplantation
  8. Canine immunogenetics
  9. A2-step approach to myeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing
  10. Adenovirus DNA polymerase is recognized by human CD8+T cells
  11. Purification of melanoma reactive T cell by using a monocyte-based solid phase T-cell selection system for adoptive therapy
  12. In vitro methods for generating highly purified EBV associated tumor antigen-specific T cells by using solid phase T cell selection system for immunotherapy
  13. Port site metastasis of B-cell lymphoma: A first occurrence or an underreported complication?
  14. T Cell Repertoire Complexity Is Conserved after LLME Treatment of Donor Lymphocyte Infusions
  15. Sequence of the canine major histocompatibility complex region containing non-classical class I genes
  16. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: A phase I study
  17. Activity of single-agent melphalan 220-300 mg/m2with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma
  18. Cytoprotection in acute myelogenous leukemia (AML) therapy
  19. Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation
  20. Molecular Organization of the Canine Major Histocompatibility Complex